Does age matter in the selection of treatment for men with early-stage prostate cancer?

Andre Konski, Debra Eisenberg, Eric Horwitz, Alexandra Hanlon, Alan Pollack, Gerald Hanks

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

BACKGROUND. The specific aim of the current study was to compare freedom from biochemical failure, distant metastases-free survival, and overall survival in men age ≤55 years, men ages 60 to 69 years, and men age ≥70 years presenting with localized prostate cancer. METHODS. A matched pair analysis compared patients age ≤55 years (Group 1) who were treated with 3-dimension conformal radiation without androgen deprivation to men age ≥60 years and <70 years (Group 2), and men age ≥70 years (Group 3) who were treated at the Fox Chase Cancer Center between November 1989 and October 2001. The groups were matched for disease stage (T1/T2b vs. T2C/T3), Gleason grade (2-6 vs. 7-10), radiation dose (<70 Gray [Gy] vs. ≥70-76 Gy vs. ≥76 Gy), and pretreatment prostate-specific antigen (PSA) level. Estimates of outcome were accomplished using Kaplan-Meier methodology and compared by age group using the log-rank test. RESULTS. Eighty-four men were identified according to the selection criteria. No statistically significant difference was found in the 5-year overall survival rates for Group 1, Group 2, and Group 3 (94%, 95%, and 87%, respectively) or the 5-year rate of freedom from biochemical failure in Group 1, Group 2, and Group 3 (82%, 76%, and 70%, respectively), or freedom from distant metastases (96%, 97%, and 98%, respectively). CONCLUSIONS. Men age ≤55 years who present with localized prostate cancer do not appear to have a worse prognosis. External beam radiation therapy appears to be a viable treatment alternative and should be offered to men age ≤55 years who present with organ-confined prostate cancer.

Original languageEnglish
Pages (from-to)2598-2602
Number of pages5
JournalCancer
Volume106
Issue number12
DOIs
StatePublished - Jun 15 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Therapeutics
Radiation
Neoplasm Metastasis
Matched-Pair Analysis
Survival
Prostate-Specific Antigen
Patient Selection
Androgens
Research Design
Radiotherapy
Survival Rate
Age Groups
Neoplasms

Keywords

  • Age
  • Early stage
  • External beam radiation therapy
  • Prostate cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Konski, A., Eisenberg, D., Horwitz, E., Hanlon, A., Pollack, A., & Hanks, G. (2006). Does age matter in the selection of treatment for men with early-stage prostate cancer? Cancer, 106(12), 2598-2602. https://doi.org/10.1002/cncr.21923

Does age matter in the selection of treatment for men with early-stage prostate cancer? / Konski, Andre; Eisenberg, Debra; Horwitz, Eric; Hanlon, Alexandra; Pollack, Alan; Hanks, Gerald.

In: Cancer, Vol. 106, No. 12, 15.06.2006, p. 2598-2602.

Research output: Contribution to journalArticle

Konski, A, Eisenberg, D, Horwitz, E, Hanlon, A, Pollack, A & Hanks, G 2006, 'Does age matter in the selection of treatment for men with early-stage prostate cancer?', Cancer, vol. 106, no. 12, pp. 2598-2602. https://doi.org/10.1002/cncr.21923
Konski, Andre ; Eisenberg, Debra ; Horwitz, Eric ; Hanlon, Alexandra ; Pollack, Alan ; Hanks, Gerald. / Does age matter in the selection of treatment for men with early-stage prostate cancer?. In: Cancer. 2006 ; Vol. 106, No. 12. pp. 2598-2602.
@article{72b497a5cb3f40d281691ffe16f25c3a,
title = "Does age matter in the selection of treatment for men with early-stage prostate cancer?",
abstract = "BACKGROUND. The specific aim of the current study was to compare freedom from biochemical failure, distant metastases-free survival, and overall survival in men age ≤55 years, men ages 60 to 69 years, and men age ≥70 years presenting with localized prostate cancer. METHODS. A matched pair analysis compared patients age ≤55 years (Group 1) who were treated with 3-dimension conformal radiation without androgen deprivation to men age ≥60 years and <70 years (Group 2), and men age ≥70 years (Group 3) who were treated at the Fox Chase Cancer Center between November 1989 and October 2001. The groups were matched for disease stage (T1/T2b vs. T2C/T3), Gleason grade (2-6 vs. 7-10), radiation dose (<70 Gray [Gy] vs. ≥70-76 Gy vs. ≥76 Gy), and pretreatment prostate-specific antigen (PSA) level. Estimates of outcome were accomplished using Kaplan-Meier methodology and compared by age group using the log-rank test. RESULTS. Eighty-four men were identified according to the selection criteria. No statistically significant difference was found in the 5-year overall survival rates for Group 1, Group 2, and Group 3 (94{\%}, 95{\%}, and 87{\%}, respectively) or the 5-year rate of freedom from biochemical failure in Group 1, Group 2, and Group 3 (82{\%}, 76{\%}, and 70{\%}, respectively), or freedom from distant metastases (96{\%}, 97{\%}, and 98{\%}, respectively). CONCLUSIONS. Men age ≤55 years who present with localized prostate cancer do not appear to have a worse prognosis. External beam radiation therapy appears to be a viable treatment alternative and should be offered to men age ≤55 years who present with organ-confined prostate cancer.",
keywords = "Age, Early stage, External beam radiation therapy, Prostate cancer, Survival",
author = "Andre Konski and Debra Eisenberg and Eric Horwitz and Alexandra Hanlon and Alan Pollack and Gerald Hanks",
year = "2006",
month = "6",
day = "15",
doi = "10.1002/cncr.21923",
language = "English",
volume = "106",
pages = "2598--2602",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Does age matter in the selection of treatment for men with early-stage prostate cancer?

AU - Konski, Andre

AU - Eisenberg, Debra

AU - Horwitz, Eric

AU - Hanlon, Alexandra

AU - Pollack, Alan

AU - Hanks, Gerald

PY - 2006/6/15

Y1 - 2006/6/15

N2 - BACKGROUND. The specific aim of the current study was to compare freedom from biochemical failure, distant metastases-free survival, and overall survival in men age ≤55 years, men ages 60 to 69 years, and men age ≥70 years presenting with localized prostate cancer. METHODS. A matched pair analysis compared patients age ≤55 years (Group 1) who were treated with 3-dimension conformal radiation without androgen deprivation to men age ≥60 years and <70 years (Group 2), and men age ≥70 years (Group 3) who were treated at the Fox Chase Cancer Center between November 1989 and October 2001. The groups were matched for disease stage (T1/T2b vs. T2C/T3), Gleason grade (2-6 vs. 7-10), radiation dose (<70 Gray [Gy] vs. ≥70-76 Gy vs. ≥76 Gy), and pretreatment prostate-specific antigen (PSA) level. Estimates of outcome were accomplished using Kaplan-Meier methodology and compared by age group using the log-rank test. RESULTS. Eighty-four men were identified according to the selection criteria. No statistically significant difference was found in the 5-year overall survival rates for Group 1, Group 2, and Group 3 (94%, 95%, and 87%, respectively) or the 5-year rate of freedom from biochemical failure in Group 1, Group 2, and Group 3 (82%, 76%, and 70%, respectively), or freedom from distant metastases (96%, 97%, and 98%, respectively). CONCLUSIONS. Men age ≤55 years who present with localized prostate cancer do not appear to have a worse prognosis. External beam radiation therapy appears to be a viable treatment alternative and should be offered to men age ≤55 years who present with organ-confined prostate cancer.

AB - BACKGROUND. The specific aim of the current study was to compare freedom from biochemical failure, distant metastases-free survival, and overall survival in men age ≤55 years, men ages 60 to 69 years, and men age ≥70 years presenting with localized prostate cancer. METHODS. A matched pair analysis compared patients age ≤55 years (Group 1) who were treated with 3-dimension conformal radiation without androgen deprivation to men age ≥60 years and <70 years (Group 2), and men age ≥70 years (Group 3) who were treated at the Fox Chase Cancer Center between November 1989 and October 2001. The groups were matched for disease stage (T1/T2b vs. T2C/T3), Gleason grade (2-6 vs. 7-10), radiation dose (<70 Gray [Gy] vs. ≥70-76 Gy vs. ≥76 Gy), and pretreatment prostate-specific antigen (PSA) level. Estimates of outcome were accomplished using Kaplan-Meier methodology and compared by age group using the log-rank test. RESULTS. Eighty-four men were identified according to the selection criteria. No statistically significant difference was found in the 5-year overall survival rates for Group 1, Group 2, and Group 3 (94%, 95%, and 87%, respectively) or the 5-year rate of freedom from biochemical failure in Group 1, Group 2, and Group 3 (82%, 76%, and 70%, respectively), or freedom from distant metastases (96%, 97%, and 98%, respectively). CONCLUSIONS. Men age ≤55 years who present with localized prostate cancer do not appear to have a worse prognosis. External beam radiation therapy appears to be a viable treatment alternative and should be offered to men age ≤55 years who present with organ-confined prostate cancer.

KW - Age

KW - Early stage

KW - External beam radiation therapy

KW - Prostate cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33745204706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745204706&partnerID=8YFLogxK

U2 - 10.1002/cncr.21923

DO - 10.1002/cncr.21923

M3 - Article

C2 - 16683224

AN - SCOPUS:33745204706

VL - 106

SP - 2598

EP - 2602

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -